Missing/wrong data? Edit Wikidata item
Faculty Opinions recommendation of Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Author/s
author: John David Spence
Work details
Publication date:
December 3, 2018
Language:
Unknown
Country of origin:
Unknown
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.